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approaches to repeat screening at critical junctures such as treatment 
completion and relapse.
Patients agreed to further referrals to: % of patients
Lung support nurse 75
Further input from doctor 70
Occupational therapy 49
Social work 39
Sources of additional written information 37
Physiotherapy 29
Dietician 27
Psychology/Psychiatry 13
Pastoral Care 8
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Background: In 2002 national cancer registry based audit data demon-
strated that for lung cancer in Scotland there were statistically signiﬁ-
cant survival differences depending upon where the patient lived. This 
correlated with data on patterns of care, conﬁrming differences in use 
of active cancer treatment by geographical area. The West of Scotland 
Lung Cancer Network was established in 2002 with the aim of deliver-
ing consistent high quality care across all hospital units with equity of 
access to lung cancer specialists. Prospective lung cancer audit was 
established for the regional network in 2003 with a dataset including 
demographic data, treatment details and outcome. This current study 
aims to assess changes in patterns of care since 2002 and compares 
the six geographical areas within the region on quality of lung cancer 
service.
Method: On 2005 audit data eight indicators of quality of care were 
used to compare the current service across geographical areas:
1. Comprehensive lung cancer care to local population as measured by 
case ascertainment in audit compared to national cancer registry data
2. Multidisciplinary (MDT) team discussion of patient management
3. Histological diagnostic rate
4. Surgical resection rate
5. Chemotherapy use in small cell lung cancer (SCLC) patients
6. Patients receiving no active anti-cancer therapy
7. Recruitment to clinical trials
8. One year survival 
The national audit data published in 2002 provided a baseline compari-
son.
Results: Case ascertainment for the region was 82.8%, but ranged from 
63.4-96.1% across the six areas. MDT input was achieved in mean 
84.2% patients but ranged from 60.4-96.5%. Histological diagnosis 
mean rate was 81.9%, range 76.9-86.4%. Surgical resection varied 
from 6.5-22% (mean 10.7%). Chemotherapy was used in 62.4% SCLC 
patients but ranged from 35.7-73.3%. In the 2002 data 43% patients re-
ceived no active treatment which had fallen to a mean of 25% in 2005 
but areas varied 19.4-35.1%. Recruitment to trials was poor average 
1.6%, range 0-4.2%. One year survival for 2002 ranged from 21.6-
25.8%, but for 2004 patients across the region ranged from 26.7-33%.
Conclusions: With the development of a lung cancer network the treat-
ment rates and survival for lung cancer can be shown to be improved. 
Geographical differences in care still persist however and this assess-
ment will be used to stimulate further improvements.
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Background: Lung cancer symptoms can be very burdensome for 
patients with SCLC and can result in impairment in quality of life and 
health status. PSALC is a symptom scale developed for use in patients 
with SCLC for assessment of 9 symptoms (shortness of breath, cough, 
chest pain, hemoptysis, appetite loss, sleep interference, hoarseness, 
fatigue, interference with daily activities) scored from 1 (not at all) to 
4 (very much), but it has not been formally validated. The objective of 
this study is to evaluate the validity of the PSALC through a psycho-
metric analysis of trial data.
Methods: Data were analyzed from a randomized, open-label, 
multicenter trial with 71 patients with SCLC receiving oral topotecan 
with best supportive care (BSC) and 70 patients receiving BSC alone. 
PSALC and EQ-5D were administered to patients at baseline and at 
3-week intervals at subsequent visits. Internal consistency, construct 
validity, reliability, and responsiveness to change in clinical status were 
evaluated.
Results: Factor analysis using baseline PSALC evaluations (n=132) 
indicated that all 9 symptom questions can be summarized as one fac-
tor, therefore, PSALC total score was used for psychometric analysis. 
Weighted Cronbach’s alpha from all visits was 0.78. Construct validity 
was supported by the association of higher PSALC total score (worse 
symptoms) with worse ECOG performance status (Table). The PSALC 
total score was also signiﬁcantly correlated with EQ-5D utility index 
and EQ-5D VAS score at baseline and at follow-up visits (Pearson 
correlation coefﬁcient [CC]=-0.598 with EQ-5D utility index; Pear-
son CC=-0.594 with EQ-5D VAS score; using evaluations at all time 
points; both p<0.0001). Reliability was supported by intraclass CC of 
0.68 for PSALC total scores evaluated before any change in clinical 
status, and concordance CC of 0.69, calculated using PSALC total 
scores at baseline and before ﬁrst visit. The PSALC total score was 
responsive to change in clinical status from baseline to tumor re-
sponse (responsiveness statistic [RS] =-0.99) and to tumor progression 
(RS=0.94).
